How can companies adapt their single evidence package at launch into multiple, tailored versions for HTAs that vary across different countries and regions?
Cristiana Toader
Advertisement
Cristiana Toader is Manager at Executive Insight.
Articles by Cristiana Toader
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
JP Morgan 2026 Preview: Novartis’ History of Expansion
2
JP Morgan 2026 Preview: Bristol Myers Squibb’s Continued Growth
3
AstraZeneca Reaches $2 Billion License Agreement with Jacobio Pharma for Pan-KRAS Inhibitor
4
Data Quality in Drug Development: The Missing Foundation to Realize AI’s Promise in Clinical Trials
5